EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro

Kevin J Lee iD, Sagar Chokshi, Tanvi Joshi, Mackenzie Cummings iD, Catherine E Lyons iD, Mary Howard Singleton, Elizabeth Catranis, Luciana Madiera da Silva, Faisal Hayat iD, Marie Migaud iD, Jennifer Scalici

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26041719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kevin J Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: USA Health Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA. Hauptthemen laut MEDLINE: NAD, Niacinamide, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: USA Health Mitchell Cancer Institute, Norma Livingston Ovarian Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dihydronicotinamide rioside (NRH), the reduced form of nicotinamide riboside (NR), is a recently identified, naturally occurring precursor of arguably the most crucial cofactor for cellular function, nicotinamide adenine dinucleotide (NAD+). Recent investigation suggests that NRH is more adept at increasing NAD+ stores than traditional NAD+ precursors, and such extreme NAD+ boosting via NRH supplementation induces cytotoxicity in certain cellular contexts. It has also been shown that the lack of functional BRCA protein in epithelial ovarian cancer (EOC) directly impacts intracellular NAD+ levels. Given that altered cellular metabolism and DNA repair mechanisms are central alterations in EOC, and these processes are functionally dependent on NAD+, we sought to assess whether NRH supplementation in EOC cell lines enhanced cellular cytotoxicity alone and in combination with standard therapeutic agents. Significant cytotoxicity was noted in NRH treated cells (~40%) with minimal cell death in the nicotinic acid (NA)-treated lines. Levels of NAD(P)H were confirmed to have increased with NRH supplementation, albeit at different levels among the different cell lines. Overall, the cytotoxicity associated with NRH supplementation appears to be independent of ROS generation. Strikingly, NRH supplementation enhanced cytotoxicity of carboplatin in OVCAR8, but not ES2 or SKOV3. Paclitaxel cytotoxicity was also enhanced by the addition of NRH in OVCAR8, but not ES2 or SKOV3 cell lines. NA supplementation had no effect on baseline treatment-induced cytotoxicity. PARP inhibition by olaparib requires NAD+. Interestingly, NRH supplementation enhanced olaparib cytotoxicity in SKOV3 and OVCAR8, but not ES2 cells. NRH in combination with olaparib completely altered mitochondrial respiration, thereby shutting down energy consumption, which would lead to cell death. Coupled together with expression data of key enzymes required for NRH/NAD metabolism, this could be key in understanding mechanisms of cell death with NRH supplementation. Here, we showed that in the context of EOC, exploitation of the NAD+ bioenergetic phenotype through NRH supplementation is a biologically feasible strategy to enhance the response of traditional therapy with potentially minimal toxicity. These data suggest several potential mechanisms by which cellular NAD+ availability impacts treatment efficacy and resistance and highlights the potential utility of NAD+ metabolomics as a biomarker to guide treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NADNiacinamideOvarian NeoplasmsCarcinoma, Ovarian EpithelialPyrimidinesAntineoplastic AgentsHumansCell Line, TumorFemalePhthalazinesPiperazinesReactive Oxygen SpeciesCell SurvivalPyridinium Compounds

Stichwörter der Autor:innen

NAD+NRHPARP inhibitorsolaparibovarian cancer

Substanzen

NADNiacinamidenicotinamide-beta-ribosidePyrimidinesolaparibPhthalazinesPiperazinesAntineoplastic AgentsReactive Oxygen SpeciesPyridinium Compounds

Autor:innen und Institutionen

  • USA Health Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
  • Department of Pharmacology, University of South Alabama, Mobile, AL 36688, USA.
  • Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.

ORCID-Profile: Kevin J Lee, Mackenzie Cummings, Catherine E Lyons, Faisal Hayat, Marie Migaud

Förderung

  • USA Health Mitchell Cancer Institute
  • Norma Livingston Ovarian Cancer Foundation

Zitieren

APA

Lee, K. J., Chokshi, S., Joshi, T., Cummings, M., Lyons, C. E., Singleton, M. H., Catranis, E., Madiera da Silva, L., Hayat, F., Migaud, M., & Scalici, J. (2025). NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041719

Vancouver

Lee KJ, Chokshi S, Joshi T, Cummings M, Lyons CE, Singleton MH, et al. NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041719

BibTeX
@article{Lee2025,
  author = {Lee, Kevin J and Chokshi, Sagar and Joshi, Tanvi and Cummings, Mackenzie and Lyons, Catherine E and Singleton, Mary Howard and Catranis, Elizabeth and Madiera da Silva, Luciana and Hayat, Faisal and Migaud, Marie and Scalici, Jennifer},
  title = {NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26041719}
}
Kostenlos starten →